Biogen and Denali announced that their Phase 2b LUMA study of BIIB122, a drug targeting early-stage Parkinson's disease, did not meet its primary or secondary endpoints, showing no slowing of disease progression compared to placebo. Despite good safety and biomarker results, the companies will discontinue BIIB122 development for idiopathic Parkinson's disease but will continue a related Phase 2a study in patients with a genetic LRRK2 variant. The findings will be shared at an upcoming scientific conference, contributing to Parkinson's research. Data from the ongoing BEACON study is expected in early 2027, which may inform future therapeutic strategies.
Biogen and Denali announced that their Phase 2b LUMA study of BIIB122 (DNL151) in early-stage Parkinson's disease did not meet its primary or secondary endpoints, showing no slowing of disease progression compared to placebo. Despite good safety and ...
More than 50 companies are actively developing over 55 new drugs for pulmonary arterial hypertension (PAH), a serious lung-related heart condition. These drugs are in various clinical trial stages, with several in late-stage development, aiming to im...
Levi & Korsinsky has started an investigation into Biogen Inc. following the failure of its CELIA trial for the BIIB080 Alzheimer's drug, which did not meet its primary endpoint. This led to a sharp decline in Biogen's stock as investors reassessed t...
Biogen's shares fell 6.4% on May 14, 2026, after the company announced that its Phase 2 CELIA trial for the drug diranersen failed to meet the primary dose-response endpoint related to clinical dementia rating at Week 76. Despite the setback, Biogen ...
